Similar Articles
31 Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma
32 Global scientific trends on hepatocellular carcinoma research from 2004 to 2023: A bibliometric and visualized analysis
33 Development and validation of a nomogram for predicting postoperative venous thromboembolism risk in patients with hepatocellular carcinoma
34 Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
35 Regulator of chromosome condensation 1 promotes hepatocellular carcinoma proliferation via cell-division-cycle-associated-8 dependent phosphoinositide 3-kinase/protein kinase B signaling
36 Preoperative model for predicting early recurrence in hepatocellular carcinoma patients using radiomics and deep learning: A multicenter study
37 Risk of hepatocellular carcinoma according to body mass index and waist circumference in nonalcoholic fatty liver disease
38 Artificial intelligence to predict hepatocellular carcinoma risk in cirrhosis
39 Mechanisms underlying hepatocellular carcinoma progression through N6-methyladenosine modifications of long non-coding RNA
40 Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA